Cone replacement is essential for treating loss of central vision.
While cone cells are less abundant than their rod counterparts, humans are more critically dependent on cones for optimal vision performance.
Cones mediate the functions of central vision, high-acuity vision and color vision, whereas rods mediate low light and peripheral vision.
And despite the crucial role of cones in the function of the retina, patients with central vision loss from Inherited Retinal Disease (IRD) or “dry” Age-related Macular Degeneration (AMD) have no therapeutic options for restoring vision.
OkuloVision set out to challenge this paradigm. We’re developing breakthrough Cone Progenitor Cell (CPC) therapy - to not only preserve central vision, but to restore and regenerate damaged cone cells and to ultimately reverse vision loss altogether.
CPCs sit in a developmental sweet spot, and are unique among stem-cell based therapies. CPCs are:
Highly proliferative and committed to cone fate
Without potential for teratoma formation or aberrant differentiation
